First Results of Phase I/II Studies Evaluating Viral Vector-Based Heterologous Prime/Boost Immunotherapy Against Predicted HLA Class I Neoantigens Demonstrate CD8 T Cell Responses In Patients with Advanced Cancers

M.L Johnson,M Zhong,S Chan,A Spira,A Malloy,C Drake,B Henick,E Bournazou,E Maloney,A.R Ferguson,M Hart,K Caldwell,D Catenacci,C Palmer,M Ingham,D.P Carbone,P Basciano,A Yang

doi:10.1093/annonc/mdz451.002

First Results of Phase I/II Studies Evaluating Viral Vector-Based Heterologous Prime/Boost Immunotherapy Against Predicted HLA Class I Neoantigens Demonstrate CD8 T Cell Responses In Patients with Advanced Cancers

M.L Johnson, M Zhong + Show 16 more

Open Access

https://doi.org/10.1093/annonc/mdz451.002

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Dec 1, 2019
Citations: 2	License type: publisher-specific-oa

Affiliation: Virginia Cancer Institute, Columbia University Irving Medical Center, New York Hospital Queens, NewYork–Presbyterian Hospital, University of Chicago Medical Center

#Research Grant #Stock Options + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

First Results of Phase I/II Studies Evaluating Viral Vector-Based Heterologous Prime/Boost Immunotherapy Against Predicted HLA Class I Neoantigens Demonstrate CD8 T Cell Responses In Patients with Advanced Cancers

Full Text